Skip to main content

Loading market data...

GH

Guardant Health, Inc.

NASDAQ • United states

$162.59

+$4.71

(+2.98%)

Source: Yahoo Finance · Quote time Oct 20, 2026 20:00 GMT+0000

Catalyst Evidence

No verified catalyst stored yet

Click “View” to see the stored chain of evidence (if available).

Management
Credibility
Score

Guardant Health, Inc. (GH)

Unavailable

Quotes may be delayed

$21.82B

Market Cap

1,308,529

Volume

Unavailable

P/E Ratio

Unavailable

Div Yield

Guardant Health, Inc. Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: 3100 HANOVER STREET, PALO ALTO, CA
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

14 Aug 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Guardant Health, Inc..

31 Jul 2026

Guardant Health, Inc. filed Form 10-Q

Guardant Health, Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.

31 Jul 2026

Guardant Health, Inc. reported Operating or financial results

Guardant Health, Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

29 Jul 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Guardant Health, Inc..

19 Jun 2026

Guardant Health, Inc. reported Shareholder voting results

Guardant Health, Inc. filed an 8-K covering shareholder voting results.

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$1.05B

Total assets (USD)$1.91B

Total liabilities (USD)$2.14B

Shareholders' equity (USD)−$222.87M

Long-term debt (USD)$1.50B

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 30 Jun 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q2 2026	$334.98M	−$129.12M	−$120.14M	−$0.90	10-Q · 30 Jul 2026
Q1 2026	$301.67M	−$121.35M	−$112.08M	−$0.85	10-Q · 7 May 2026
Q4 2025	$281.27M	−$120.81M	−$128.52M	Unavailable	10-K · 19 Feb 2026
Q3 2025	$265.20M	−$98.99M	−$92.73M	−$0.74	10-Q · 29 Oct 2025
Q2 2025	$232.09M	−$106.41M	−$99.90M	−$0.80	10-Q · 30 Jul 2025
Q1 2025	$203.47M	−$111.04M	−$95.16M	−$0.77	10-Q · 30 Apr 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $203.29

25.0% upside potential

📈

Strong Buy

Unavailable

👍

Buy

19

⏸️

Hold

0

📉

Sell

0

19 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 21 Oct 2026, 09:50 UTC Targets range 180.00–225.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

17

Oct 2026

Hidalgo Medina Manuel

Director

Option exercise

Unavailable per share

232 shares

16

Oct 2026

Tariq Musa

Director

Open-market sale

$165.88 per share

116 shares

15

Oct 2026

Tariq Musa

Director

Option exercise

Unavailable per share

250 shares

14

Oct 2026

Azar Alex M II

Director

Open-market sale

$159.89 per share

69 shares

12

Oct 2026

Azar Alex M II

Director

Option exercise

Unavailable per share

137 shares

1

Oct 2026

Saia John G.

Chief Legal Officer

Option exercise

Unavailable per share

7,063 shares

1

Oct 2026

Saia John G.

Chief Legal Officer

Tax withholding

$174.75 per share

3,706 shares

1

Oct 2026

Monroe Terilyn J.

Chief People Officer

Option exercise

Unavailable per share

4,019 shares

1

Oct 2026

Monroe Terilyn J.

Chief People Officer

Tax withholding

$174.75 per share

2,098 shares

1

Oct 2026

Kalia Kumud

Chief Information Officer

Option exercise

Unavailable per share

6,046 shares

Top Shareholders

Vanguard Group Inc

12,160,768 shares

2.116% change

12/31/2025

Blackrock, Inc.

7,622,935 shares

-34.022% change

6/30/2026

Price T Rowe Associates Inc /Md/

6,514,952 shares

-7.243% change

6/30/2026

Vanguard Capital Management Llc

5,755,857 shares

2.341% change

6/30/2026

Fmr Llc

5,488,272 shares

33.337% change

6/30/2026

Vanguard Portfolio Management Llc

5,445,785 shares

-6.718% change

6/30/2026

Invesco Ltd.

4,429,755 shares

-10.446% change

6/30/2026

Goldman Sachs Group Inc

3,775,895 shares

-14.878% change

6/30/2026

Two Sigma Investments, Lp

3,719,301 shares

-12.064% change

6/30/2026

Capital International Investors

3,399,604 shares

-2.347% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 21 Oct 2026, 09:50 UTC· 21 hours ago

Research coverage and investment tools

Guardant Health, Inc. (GH) is a stock listed on the Nasdaq in the United States, in the Health Care sector (Medical Specialities). Its last price was US$162.59 on 20 Oct 2026. That is 77% of the way from its 52-week low of US$66.59 to its 52-week high of US$191.05. Its market capitalisation was US$21.82 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q2 2026	$334.98M	−$129.12M	−$120.14M	−$0.90	—	-38.5%	−$69.54M	10-Q · 30 Jul 2026 (opens in a new tab)
Q1 2026	$301.67M	−$121.35M	−$112.08M	−$0.85	—	-40.2%	−$71.20M	10-Q · 7 May 2026 (opens in a new tab)
Q4 2025	$281.27M	−$120.81M	−$128.52M	Unavailable	—	-43.0%	−$54.22M	10-K · 19 Feb 2026 (opens in a new tab)
Q3 2025	$265.20M	−$98.99M	−$92.73M	−$0.74	—	-37.3%	−$45.76M	10-Q · 29 Oct 2025 (opens in a new tab)
Q2 2025	$232.09M	−$106.41M	−$99.90M	−$0.80	—	-45.9%	−$65.93M	10-Q · 30 Jul 2025 (opens in a new tab)
Q1 2025	$203.47M	−$111.04M	−$95.16M	−$0.77	—	-54.6%	−$67.15M	10-Q · 30 Apr 2025 (opens in a new tab)

Cash and equivalents: $1.05B
Total assets: $1.91B
Total liabilities: $2.14B
Shareholders' equity: −$222.87M
Long-term debt: $1.50B

SCHEDULE 13G/A · 14 Aug 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Guardant Health, Inc..
10-Q · 31 Jul 2026

Guardant Health, Inc. filed Form 10-Q (opens in a new tab)

Guardant Health, Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.
8-K · 31 Jul 2026

Guardant Health, Inc. reported Operating or financial results (opens in a new tab)

Guardant Health, Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.
SCHEDULE 13G/A · 29 Jul 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Guardant Health, Inc..
8-K · 19 Jun 2026

Guardant Health, Inc. reported Shareholder voting results (opens in a new tab)

Guardant Health, Inc. filed an 8-K covering shareholder voting results.

Insider	Date	Transaction	Shares	Average price	Filing
Hidalgo Medina Manuel Director	17 Oct 2026	Option exercise (M)	+232	—	Form 4 (opens in a new tab)
Tariq Musa Director	16 Oct 2026	Open-market sale (S)	−116	$165.88	Form 4 (opens in a new tab)
Tariq Musa Director	15 Oct 2026	Option exercise (M)	+250	—	Form 4 (opens in a new tab)
Azar Alex M II Director	14 Oct 2026	Open-market sale (S)	−69	$159.89	Form 4 (opens in a new tab)
Azar Alex M II Director	12 Oct 2026	Option exercise (M)	+137	—	Form 4 (opens in a new tab)
Saia John G. Chief Legal Officer	1 Oct 2026	Option exercise (M)	+7,063	—	Form 4 (opens in a new tab)
Saia John G. Chief Legal Officer	1 Oct 2026	Tax withholding (F)	−3,706	$174.75	Form 4 (opens in a new tab)
Monroe Terilyn J. Chief People Officer	1 Oct 2026	Option exercise (M)	+4,019	—	Form 4 (opens in a new tab)
Monroe Terilyn J. Chief People Officer	1 Oct 2026	Tax withholding (F)	−2,098	$174.75	Form 4 (opens in a new tab)
Kalia Kumud Chief Information Officer	1 Oct 2026	Option exercise (M)	+6,046	—	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Vanguard Group Inc	12/31/2025	12,160,768	2.116%
Blackrock, Inc.	6/30/2026	7,622,935	-34.022%
Price T Rowe Associates Inc /Md/	6/30/2026	6,514,952	-7.243%
Vanguard Capital Management Llc	6/30/2026	5,755,857	2.341%
Fmr Llc	6/30/2026	5,488,272	33.337%
Vanguard Portfolio Management Llc	6/30/2026	5,445,785	-6.718%
Invesco Ltd.	6/30/2026	4,429,755	-10.446%
Goldman Sachs Group Inc	6/30/2026	3,775,895	-14.878%
Two Sigma Investments, Lp	6/30/2026	3,719,301	-12.064%
Capital International Investors	6/30/2026	3,399,604	-2.347%

Previous close: 157.88 USD
Day range: 155.07 – 163.57 USD
52-week range: 66.59 – 191.05 USD
Volume: 1,308,529
Market cap: $21.82B
Average volume: 1,861,847
EPS (FY 2025, diluted): −3.32 USD
Shares outstanding: 134.20M
Beta (5Y monthly): 1.66

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 20 Oct 2026, 20:00 UTC· 1 day ago

Average volume, P/E and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 06:18 UTC· 54 minutes ago

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding.

This research is not available for GH yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.